ATE151994T1 - Aufspüren und behandeln von infektionen durch verwendung von immunokonjukaten - Google Patents

Aufspüren und behandeln von infektionen durch verwendung von immunokonjukaten

Info

Publication number
ATE151994T1
ATE151994T1 AT90309319T AT90309319T ATE151994T1 AT E151994 T1 ATE151994 T1 AT E151994T1 AT 90309319 T AT90309319 T AT 90309319T AT 90309319 T AT90309319 T AT 90309319T AT E151994 T1 ATE151994 T1 AT E151994T1
Authority
AT
Austria
Prior art keywords
antibody
pathogen
diagnostic
immunoconjucates
detecting
Prior art date
Application number
AT90309319T
Other languages
English (en)
Inventor
Milton David Goldenberg
Original Assignee
Immunomedics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunomedics Inc filed Critical Immunomedics Inc
Application granted granted Critical
Publication of ATE151994T1 publication Critical patent/ATE151994T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
AT90309319T 1989-08-24 1990-08-24 Aufspüren und behandeln von infektionen durch verwendung von immunokonjukaten ATE151994T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39956689A 1989-08-24 1989-08-24

Publications (1)

Publication Number Publication Date
ATE151994T1 true ATE151994T1 (de) 1997-05-15

Family

ID=23580041

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90309319T ATE151994T1 (de) 1989-08-24 1990-08-24 Aufspüren und behandeln von infektionen durch verwendung von immunokonjukaten

Country Status (13)

Country Link
EP (1) EP0417927B1 (de)
JP (1) JPH07121880B2 (de)
KR (1) KR0179953B1 (de)
AT (1) ATE151994T1 (de)
AU (1) AU636172B2 (de)
CA (1) CA1339415C (de)
DE (1) DE69030545T2 (de)
ES (1) ES2100164T3 (de)
IE (1) IE903071A1 (de)
IL (1) IL95457A (de)
SG (1) SG46451A1 (de)
WO (1) WO1991002541A1 (de)
ZA (1) ZA906703B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5120525A (en) * 1988-03-29 1992-06-09 Immunomedics, Inc. Radiolabeled antibody cytotoxic therapy of cancer
US5194594A (en) * 1990-09-07 1993-03-16 Techniclone, Inc. Modified antibodies
CA2065658A1 (en) * 1991-04-19 1992-10-20 Tse-Wen Chang Conjugates of liposomes or microbeads and antibodies specific for t lymphocytes and their use in vivo immune modulators
GB9517758D0 (en) * 1995-08-31 1995-11-01 Imutran Ltd Compositions and their uses
ITRM960808A1 (it) * 1996-11-26 1998-05-26 Rossolini Gianmaria Immunoconiugati comprendenti anticorpi monoclonali umani o frammenti di essi per diagnosi in vivo e terapia
DE19809785C2 (de) * 1998-03-08 2000-02-10 Wolfgang Bergter Radioimmunpharmakon zur Behandlung der HIV-1-Infektion
WO2000000223A2 (de) * 1998-06-29 2000-01-06 Wolfgang Bergter ANTIVIRALE UND ANTIRETROVIRALE RADIOIMMUNPHARMAKA AUF DER BASIS VON α- UND β-STRAHLERN
CA2869088A1 (en) * 2002-02-07 2003-08-14 Massachusetts Institute Of Technology Anti-pathogen treatments
EP1419786A1 (de) 2002-11-13 2004-05-19 Bracco Imaging S.p.A. Verfahren zur quantitativen und selektiven Funktionalisierung von Immunoglobulin-Fab-Fragmenten, deren Konjugate und deren Zusammensetzungen
JP4928964B2 (ja) 2007-01-30 2012-05-09 本田技研工業株式会社 車両のスイングアーム式懸架装置

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU556548B2 (en) * 1980-03-03 1986-11-06 Milton David Goldenberg Tumor localization and therapy with labeled antibodies and antibody fragments specific to tumor-associated markers
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
CA1203164A (en) * 1982-03-09 1986-04-15 Thomas J. Mckearn Antibody conjugates
US4520226A (en) * 1982-07-19 1985-05-28 The United States Of America As Represented By The Department Of Health And Human Services Treatment of graft versus host disease using a mixture of T-lymphocyte specific monoclonal antibody: ricin conjugates
ATE61000T1 (de) * 1983-07-29 1991-03-15 Milton David Goldenberg Verfahren zur erhoehung der zielspezifizitaet in antikoerperbestimmungen und zur raeumung von nichtzielspezifischen diagnostischen und therapeutischen faktoren.
US4855227A (en) * 1985-06-07 1989-08-08 Institute For Medical Research Rapid detection of mycoplasmas
US4894227A (en) * 1986-08-01 1990-01-16 Cetus Corporation Composition of immunotoxins with interleukin-2
US4932412A (en) * 1986-12-18 1990-06-12 Immunomedics, Inc. Intraoperative and endoscopic tumor detection and therapy
WO1988009181A2 (en) * 1987-05-29 1988-12-01 Tanox Biosystems, Inc. Monoclonal antibodies neutralizing hiv-1
CA1329119C (en) * 1988-03-29 1994-05-03 Milton David Goldenberg Cytotoxic therapy
US4925648A (en) * 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions

Also Published As

Publication number Publication date
IE903071A1 (en) 1991-02-27
IL95457A0 (en) 1991-06-30
JPH04506217A (ja) 1992-10-29
JPH07121880B2 (ja) 1995-12-25
IL95457A (en) 1997-01-10
DE69030545T2 (de) 1997-08-07
EP0417927B1 (de) 1997-04-23
ZA906703B (en) 1991-06-26
CA1339415C (en) 1997-09-02
DE69030545D1 (de) 1997-05-28
WO1991002541A1 (en) 1991-03-07
KR920700686A (ko) 1992-08-10
EP0417927A1 (de) 1991-03-20
SG46451A1 (en) 1998-02-20
AU636172B2 (en) 1993-04-22
AU6408290A (en) 1991-04-03
KR0179953B1 (ko) 1999-03-20
ES2100164T3 (es) 1997-06-16

Similar Documents

Publication Publication Date Title
DK79390A (da) Anti-leukocytkonjugat og anvendelse heraf
RU96101193A (ru) Фрагменты антител в терапии
ATE151994T1 (de) Aufspüren und behandeln von infektionen durch verwendung von immunokonjukaten
DE69932084D1 (de) Antikörperfragmente zur lokalen Behandlung von Augenerkrankungen
JPS6485928A (en) Monoclonal antibody and peptide useful for therapy and diagnosis for hiv infection
Hansen et al. A mouse aminopeptidase N is a marker for antigen‐presenting cells and appears to be co‐expressed with major histocompatibility complex class II molecules
KR900013986A (ko) 종양-관련항원에 대한 모노클로날 항체(MAb_s), 이의 제조방법 및 용도
NO883306D0 (no) Farmasoeytisk aktive konjugater med forbedret bindingsspesifisitet for kroppsvev.
BR9007702A (pt) Metodo de tratamento
DE69638024D1 (de) Melanoma antigene p15 und deren anwendung in diagnostischen und therapeutischen verfahren
ATE407149T1 (de) Detoxifizierung durch intramuskulär verabreichte f(ab')2 fragmente
Seed Trypanosoma gambiense and T. equiperdum: Characterization of variant specific antigens
DE69435142D1 (de) Methoden zur Inhibition von HIV-assoziierten Krankheiten mittels monoklonaler Antikörper gegen sich selbstgerichtete zytotoxische T-Zellen
Haines et al. Preparation of specific antisera to cytomegaloviruses in goats
ATE111485T1 (de) Peptidbehandlung von hartnäckigen infektionskrankheiten.
Moroz Vipera palaestinae antivenin
SE9101863D0 (sv) Peptider, diagnostiskt antigen, vaccinkomposition och foerfarande foer selektering av hiv-stammar
ES2013665A6 (es) Procedimiento para preparar un anticuerpo monoclonal humano y metodo de uso.
RU95117092A (ru) Антитела, смесь антител, fab-фрагмент, линии гибридомных клеток, способы создания линий клеток, способ борьбы с вирусом, способ снижения уровня антигена, днк
Kalashnikov et al. Evaluation of specificity of the test for β 1-G-globulin in trophoblastic tumors by a quantitative immunoenzymic method
UA28690A (uk) Спосіб діагностики інфекційного ендокардиту стафілококової етіології

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties